Michael V. Volin Ph.D.

Professor and Chair Department of Microbiology & Immunology

Chicago College of Osteopathic Medicine
Department of Microbiology and Immunology
Science Hall 323
555 31st Street
Downers Grove, IL 60515
Office Phone (630) 515-6139
Laboratory phone (630) 515-6316
email mvolin@midwestern.edu




B.A. Biology University of Chicago 1989
Ph.D. Pathology University of Chicago 1996
Fellowship Immunopathology Northwestern University 2000

Research Summary

  1. My early publications identified novel inflammatory mediators in rheumatoid arthritis and characterized their functions. Specifically, these publications identified elevated expression of chemokines, adhesion molecules and Mucins in either human RA synovial tissue or fluids or animal models of arthritis. Additionally, novel functions in the development of inflammation were identified for some of these mediators. These publications helped identify potential novel therapeutic targets for treatment of patients with RA. I served as the primary investigator or co-investigator in all of these studies.
    • Volin MV, Shah MR, Tokuhira M, Haines III GK, Woods JM, and Koch AE: RANTES expression and contribution to monocyte chemotaxis in arthritis. 1998 Clin Immunol Immunopathol 89:44-53. PMID: 9756723.
    • Volin MV, Szekanecz Z, Halloran MM, Woods JM, Magua J, Damergis Jr. JA, Haines III GK, Crocker PR, and Koch AE: PECAM-1 and leukosialin expression correlate with heightened inflammation in rat adjuvant induced arthritis. 1999 Exp Mol Pathol 66:211-219. PMID: 10486239.
    • Ruth JH, Volin MV, Haines GK, Woodruff DC, Katschke KJ Jr, Woods JM, Park CC, Morel JCM, and Koch AE: Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. 2001 Arthritis Rheum 44: 1568-1581. PMID: 11465708.
    • Volin MV, Shahrara S, Haines III GK, Woods JM, and Koch AE: Expression of Mucin 3 and Mucin 5AC in Arthritic Synovial Tissue. 2008 Arthritis Rheum 58:46-52. PMID: 18163520.
  2. Building upon my earlier work identifying the functions of different inflammatory mediators that are elevated in rheumatoid arthritis led to studies characterizing angiogenic mediators in rheumatoid arthritis. Specifically, chemokines, tyrosine kinases, and cytokines which we identified as elevated in rheumatoid arthritis were studied for their effect on blood vessel growth and development. Angiogenesis is required to sustain the chronic inflammatory pannus that is responsible for the joint destruction in rheumatoid arthritis. Thus, by identifying angiogenic mediators we also identified future potential therapies targeting blood vessel formation. I served as the primary investigator or co-investigator in all of these studies.
    • Koch AE, Volin MV, Woods JM, Burdick MD, Harlow  LA, Woodruff DC, Kunkel SL, and Strieter RM: The C-X-C Chemokines IL-8 and ENA-78 Regulate Angiogenesis in the Rheumatoid Joint.2001 Arthritis Rheum 44: 31-40. PMID: 11212173.
    • Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, and Koch AE. Fractalkine: A novel angiogenic chemokine in rheumatoid arthritis. 2001 Am J Pathol 159:1521-1530. PMCID: PMC1850492.
    • Volin MV, Huynh N, Klosowska K, Reyes RD, and Woods JM: Fractalkine-Induced Endothelial Cell Migration Requires MAP Kinase Signaling. 2010 Pathobiology 77: 7-16. PMCID: PMC2840243.
    • Shahrara S, Volin MV, Connors MA, Haines III GK, and Koch AE: Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. 2002 Arthritis Res 4:201-208. PMCID: PMC111023.
    • Pickens SR, Volin MV, Mandelin II AM, Kolls JK , Pope RM, and  Shahrara S. IL-17 Contributes to Angiogenesis in Rheumatoid Arthritis. 2010 J Immunol 184(6):3233-3241. PMCID: PMC2857761.
  3. More recently utilizing different collaborations I have studied ocular infections and methods of ocular gene delivery.  Given the anatomic location of the cornea it is an excellent target for novel gene delivery systems.  By the same token the anterior chamber of the eye is a potential target for attachment and entry of viral pathogens. These studies utilized both animal models for gene delivery and primary human cell cultures for determining viral infection. I served as a co-investigator in all of these studies.
    • Klausner EA, Zhang Z, Chapman RL, Multack RF, and Volin MV. Ultrapure Chitosan oligomers as carriers for corneal gene transfer. 2010 Biomaterials 31:1814-1820. PMID: 19879644.
    • Klausner EA, Zhang Z, Wong SP, Chapman RL, Volin MV, and Harbottle RP. Corneal gene delivery: Chitosan oligomer as a carrier of CpG rich, CpG free, or S/MAR plasmid DNA. 2012 Journal of Gene Medicine 14:100-108. PMID: 22106057.
    • Baldwin J, Park P, Zanotti B, Volin MV, Shukla D, and Tiwari V. Susceptibility of human iris stromal cells to herpes simplex virus 1 (HSV-1) entry and inflammation. 2013 J Virol 87(7):4091-4096. PMCID: PMC3624200.
    • Baldwin J, Maus E, Zanotti B, Volin MV, Tandon R, Shukla D, and Tiwari V. Role of 3-O sulfated heparin sulfate during cytomegalovirus infection in human iris stromal cells. 2015 J Virol In Press
  4. We are also identifying the therapeutic effect of osteopathic manipulative medicine on inflammation in rat models of rheumatoid arthritis. Specifically, we are studying the effect of lymphatic pump treatment (LPT) on rats with adjuvant-induced arthritis and collagen-induced arthritis. We have presented preliminary data showing decreased swelling and clinical symptoms of arthritis with clustered LPT treatments (OMED 2014) and changes in inflammatory mediator levels in synovial tissues and peripheral blood (OMED 2012 and OMED 2014).
    • Gustafson NJ, Zanotti, B, Shah P, and Volin MV. Cytokine Response to Lymphatic Pump treatment in AIA Rats. 2012 JAOA 112(8) 554-555.
    • Larimer KV, Gustafson N, Zanotti B, and Volin MV. Lymphatic Pump treatment of rats with adjuvant-induced arthritis reduces joint inflammation and systemic inflammatory cytokine production. 2014 JAOA 114(8) e110.

Complete List of Published Work in MyBibliography: